Biomedical subjects

Nam Kim

Publications and source records attributed to Nam Kim.

10 recordsLinked to original sources

PubMed2007

Simple phase-only optical decryption with misalignment-free input.

An improved optical decryption system based on kinogram encoding is proposed. The decrypted phase image is obtained by optically descrambling the encrypted image with the decrypting phase key. Only a single Fourier lens is needed to generate intensity patterns from the decrypted phase image. The design and simulation results have confirmed the proposed technique as a novel, simple, and robust decryption architecture.

Journal Article↗

PubMed2006

Design of cascaded volume holographic gratings to increase the number of channels for an optical demultiplexer.

The design and demonstration of a holographic optical demultiplexer based on cascaded volume holographic gratings are presented. By serially adding a second holographic grating, which has a different grating period, slant angle, and center wavelength compared with those of the first grating, the operating wavelength range of the optical demultiplexer could be expanded, and, therefore, the number of channels of the holographic demultiplexer is doubled. As a result of the experiment, a 0.4 nm spaced 130- channel demultiplexer with a channel uniformity of 3.5 dB, a 3 dB bandwidth of 0.12 nm, and channel cross talk of -20 dB is experimentally achieved.

Computer-Aided Design↗

PubMed2006

Optimization of humanized IgGs in glycoengineered Pichia pastoris.

As the fastest growing class of therapeutic proteins, monoclonal antibodies (mAbs) represent a major potential drug class. Human antibodies are glycosylated in their native state and all clinically approved mAbs are produced by mammalian cell lines, which secrete mAbs with glycosylation structures that are similar, but not identical, to their human counterparts. Glycosylation of mAbs influences their interaction with immune effector cells that kill antibody-targeted cells. Here we demonstrate that human antibodies with specific human N-glycan structures can be produced in glycoengineered lines of the yeast Pichia pastoris and that antibody-mediated effector functions can be optimized by generating specific glycoforms. Glycoengineered P. pastoris provides a general platform for producing recombinant antibodies with human N-glycosylation.

Antibodies, Monoclonal↗

PubMed2005

Monodispersed core-shell Fe3O4@Au nanoparticles.

The ability to synthesize and assemble monodispersed core-shell nanoparticles is important for exploring the unique properties of nanoscale core, shell, or their combinations in technological applications. This paper describes findings of an investigation of the synthesis and assembly of core (Fe(3)O(4))-shell (Au) nanoparticles with high monodispersity. Fe(3)O(4) nanoparticles of selected sizes were used as seeding materials for the reduction of gold precursors to produce gold-coated Fe(3)O(4) nanoparticles (Fe(3)O(4)@Au). Experimental data from both physical and chemical determinations of the changes in particle size, surface plasmon resonance optical band, core-shell composition, surface reactivity, and magnetic properties have confirmed the formation of the core-shell nanostructure. The interfacial reactivity of a combination of ligand-exchanging and interparticle cross-linking was exploited for molecularly mediated thin film assembly of the core-shell nanoparticles. The SQUID data reveal a decrease in magnetization and blocking temperature and an increase in coercivity for Fe(3)O(4)@Au, reflecting the decreased coupling of the magnetic moments as a result of the increased interparticle spacing by both gold and capping shells. Implications of the findings to the design of interfacial reactivities via core-shell nanocomposites for magnetic, catalytic, and biological applications are also briefly discussed.

Ferric Compounds↗

PubMed2005

Translational crossroads for biomarkers.

A group of investigators met at a Specialized Programs of Research Excellence Workshop to discuss key issues in the translation of biomarker discovery to the development of useful laboratory tests for cancer care. Development and approval of several new markers and technologies have provided informative examples that include more specific markers for prostate cancer, more sensitive tests for ovarian cancer, more objective analysis of tissue architecture and an earlier indication of response to treatment in breast cancer. Although there is no clear paradigm for biomarker development, several principles are clear. Marker development should be driven by clinical needs, including early cancer detection, accurate pretreatment staging, and prediction of response to treatment, as well as monitoring disease progression and response to therapy. Development of a national repository that uses carefully preserved, well-annotated tissue specimens will facilitate new marker development. Reference standards will be an essential component of this process. Both hospital-based and commercial laboratories can play a role in developing biomarkers from discovery to test validation. Partnering of academe and industry should occur throughout the process of biomarker development. The National Cancer Institute is in a unique position to bring together academe, industry, and the Food and Drug Administration to (a) define clinical needs for biomarkers by tumor type, (b) establish analytic and clinical paradigms for biomarker development, (c) discuss ways in which markers from different companies might be evaluated in combination, (d) establish computational methods to combine data from multiple biomarkers, (e) share information regarding promising markers developed in National Cancer Institute-supported programs, and (f) exchange data regarding new platforms and techniques that can accelerate marker development.

Antineoplastic Agents↗

PubMed2005

Holographic polarization-selective module based on a small dove prism coupler for magneto-optical pickup heads.

A new structure for polarization-selective elements, consisting of two holographic gratings and a Dove prism coupler, is proposed. The absence of a multistage waveguide and the benefits of compact size and lightweight volume are the outstanding features of the new structure. Based on the coupled-wave theory, the analysis and design of the structure are discussed in detail to calculate the required index modulation. Several parameters, such as the recording intensity, the exposure time, and the recording angles for the fabrication of the proposed element, are determined. Under these conditions, the element is fabricated in Dupont photopolymer HRF-150-38 material and with an operating wavelength of 532 nm. A simplified pickup head is constructed to evaluate the performance of the fabricated element.

Journal Article↗

PubMed2004

Effects of apodization on a holographic demultiplexer based on a photopolymer grating.

An investigation of the effects of apodization on a holographic demultiplexer that is based on a photopolymer grating is presented. Uniform and Gaussian apodized gratings are fabricated in a DuPont HRF-150-38 photopolymer. From the theoretical and experimental results, the spectral response of the apodized grating has a larger main lobe but lower sidelobes than those in the uniform-grating case. A 42-channel demultiplexer that is based on the Gaussian apodized grating with an 0.4-nm channel spacing is demonstrated. A cross-talk level of -30 dB and an interchannel uniformity of 1.5 dB are archived in the wavelength range of approximately 1550 nm.

Journal Article↗

PubMed2003

Fano resonance in crossed carbon nanotubes.

We report the observation of the resonant transport in multiwall carbon nanotubes in a crossed geometry. The resonant transport is manifested by an asymmetric peak in the differential conductance curve. The observed asymmetric conductance peak is well explained by the Fano resonance originating from the scattering at the contact region of the two nanotubes. The conductance peak depends sensitively on the external magnetic field and exhibits Aharonov-Bohm-type oscillation.

Journal Article↗

PubMed2003

A large malignant insulinoma: case report with endosonographic, immunohistochemical and ultrastructural features.

Malignant insulinoma in the beta cells of the pancreatic islet is rare and usually presented as hypoglycemia. We report a case of large malignant insulinoma in a 53-year-old Korean woman. A presumptive clinical diagnosis was made before surgery, based on the high plasma insulin-to-glucose ratio and a large solitary heterogeneous pancreatic mass by abdominal computed tomography and endosonography. The tumor measured 5.8 x 4.7 x 4.5 cm in dimension and showed capsular invasions and metastases in two of four peripancreatic lymph nodes. The tumor cells were strongly immunoreactive to insulin and had a high Ki-67 labeling index (13%) and atypical membranous electron-dense granules, ranging from 120 to 400 nm in diameter, in the cytoplasm on electron microscopy. The patient was treated by distal pancreatectomy with splenectomy and rapidly recovered without neurohypoglycemic symptoms. This case showed not only lymph node metastases, the most reliable parameter for malignancy in pancreatic endocrine tumors, but also other valid diagnostic clues, such as high Ki-67 labeling index, heterogeneous enodosonographic findings, capsular invasions with large tumor and pure atypical secretory granules.

Biopsy, Needle↗

PubMed2002

Telomerase activity in stage II colorectal carcinoma.

BACKGROUND: Telomerase is a ribonucleoprotein polymerase that adds telomeric repeats to chromosome ends. This enzyme is deficient in the majority of normal somatic cells, but often is reactivated during tumorigenesis. In the current study, the authors examined telomerase activity in human American Joint Committee on Cancer Stage II colorectal carcinomas and correlated it with traditional prognostic indicators and disease outcome. METHODS: The telomerase repeat amplification protocol (TRAP) was employed to determine telomerase activity in 122 surgical specimens (from 77 male and 45 female patients) of human Stage II colorectal carcinoma. The primary site of the tumor was the colon in 52 cases and the rectum in 70 cases. Telomerase activity was correlated with traditional prognostic indicators such as gender, age, T classification, tumor size, tumor grade, and disease outcome (overall survival and disease-free survival). The Median follow-up for patients who still were alive was 5.8 years. RESULTS: Telomerase activity was detected in 80% of the tumors (98 of 122 tumors). Telomerase-positive patients differed from telomerase-negative patients in that they tended to be female (41% vs. 21%; P = 0.1), presented with primary tumors of the colon more frequently (49% vs. 17%; P = 0.01), and had a higher T classification (T(4)) (62% vs. 38%; P = 0.04). Univariate and multivariate analyses demonstrated a correlation between telomerase activity and disease-free survival (P = 0.05). CONCLUSIONS: Although a large percentage of Stage II colorectal carcinoma samples were positive for telomerase activity, the prognosis for patients with telomerase-negative tumors was found to be worse than that for patients with telomerase-positive tumors.

Adult↗